Weight Loss: Over 6 months, patients on exenatide lost on average ~45 kg (811 lbs), whereas those on comparator therapies often lost little or even gained weight ( [6] ) ( [61] )
Additionally, both compounds can be sourced from similar dietary foods, particularly meats, and other animal products, making them accessible through both supplementation and nutrition
Before digging deeper, heres a quick refresher: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist
Future research should focus on large, multicentre trials, optimization of pharmacokinetics and comprehensive safety profiling to substantiate the efficiency in various patient populations and molecular subgroups
The main issue is youre not going to feel as hungry, and thats the point of this type of medication
after the shortage designations ended, 503A patient-specific compounding is discussed under a narrower framework